Professional Documents
Culture Documents
A. Eitel M. Scherrer K. Kümmerer: in Cooperation With
A. Eitel M. Scherrer K. Kümmerer: in Cooperation With
A. Eitel
M. Scherrer
K. Kümmerer
HO
!
N
O CO CH3
N OC
H N HO COOCH3
H3CO OCH3
CHO
Handling
A Practical Guide
In cooperation with
Authors:
Dipl.-Ing. (FH) Andreas Eitel
Dipl.-Ing. (FH) Martin Scherrer
Ass. Prof. Dr. rer. nat. Dipl-Chem. Klaus Kümmerer
University Hospital Freiburg
Institute for Environmental Medicine
and Hospital Epidemiology
Hugstetter Straße 55
D-79106 Freiburg, Germany
Source of supply:
Bristol-Myers Squibb Co, 1st. German Edition: May 1999 (5.000)
One Squibb Drive 2nd. German Edition: November 1999 (2.700)
New Brunswick, NJ 08903-0191 3rd. German Edition: February 2000 (3.000)
Telephone: +1-732-519-3682 1st. Austrian Edition: November 1999 (300)
Fax: +1-732-519-2897 1st. English Edition: June 1999 (3.000)
2nd. English Edition: March 2000 (3.000)
Bristol-Myers Squibb GmbH 1st. Spanish Edition: Mai 2000 (5.000)
“Cytostatic Manual”
Sapporobogen 6-8 Printed on Recystar, 100% recycled paper
80809 München Print: Kehrer Digital & Print, Freiburg, Germany
Germany Design: Berres/Stenzel/Werner, Freiburg, Germany
Fax: +49 89 12 142 392
ISBN 3-00-004032-3
2
Preface
O ncological patients are the focus of our attention and actions. In order to
effectively combat their disorder and to meet their needs, everyone involved in
their treatment must be able to perform various tasks in accordance with the latest
medical insights and practices.
Over the last few years, impressive progress has been made not only in research and
clinical application, but also in clinical and pharmaceutical practice – where we find a
growing demand for specialist skills to meet these requirements. Further training
and specialization are therefore a high priority. When addressing the handling of
cytostatic agents in pharmacies, the assessment of drug safety factors is gaining in
importance.
It is suspected that even the smallest doses of cytostatic agents have an irreversible
and cumulative effect and, although they do not have a threshold value, they
represent a low but nevertheless clearly defined risk as a consequence. For this reason,
all responsible bodies are in agreement that the risks involved in handling cytostatic
agents must be minimized.
Klaus Meier
President, International Society of Oncology Pharmacy Practitioners
3
Contents
Preface 3
Introduction 5
Cytostatic Drugs – What They Are and What They Do 6
Safe Handling of Cytostatic Drugs 9
• Management 10
• Wholesale, Pharmaceutical Shipment, and Storage 12
• Reconstitution of Intravenously Administered Cytostatics 12
• Handling of Orally Administered Cytostatic Drugs 15
• Administration 15
• Nursing of Patients Receiving Cytostatic Drugs 16
Special Requirements for Home Care 17
Disposal of Cytostatic Waste 18
Cleaning Procedures after Accidents 20
Routine Cleaning Procedures 21
First Aid 22
Environmental Impact of Cytostatic Drugs 22
4
Introduction
Introduction
This booklet does not claim to be complete and does not substitute for direct contact
with your local pharmacist. Some of the specific recommendations described may not
!
be consistent with accepted practices and/or environmental, health and safety regula-
tions in the US and several other countries. With regard to legal requirements, it is
your responsibility to be informed. For additional information – in particular, product
specific information such as safety data sheets or legal regulations – you should
contact the manufacturers or your local authorities.
A collection of forms, i.e., operating procedures to make your work easier, is also listed
in the Appendix.
The authors thank Dr. van Gemmern and Dr. Strehl from the pharmacy of the University
Hospital Freiburg, Ms. Melzer and Mr. Meier (Allgemeines Krankenhaus Hamburg-
Harburg) for their assistance in producing this monograph, as well as Mr. Metz from
Bristol-Myers Squibb GmbH for his cooperation.
5
Mode of Action
Cytostatics are drugs used to block the The mechanisms of cytostatic action
growth of cancer cells. They achieve are very likely to lead to carcinogenic,
this by influencing cell metabolism mutagenic, and teratogenic effects.
during the cell cycle (Fig. 1) so that Consequently, pregnant women should
cell division and cell reproduction is avoid all contact with cytostatic drugs.
inhibited. Cytostatics can be classified This is required by law in most
according to their action mechanisms European countries, but not in all
and their points of attack. An over- countries (e.g., in the U.S.), so it is
view of the most important groups is necessary for facilities to check local
given in Table 1 (p. 8). regulations.
G2
ase
rph
inte mit
osi
S s
prophase
-3h
-8h
-8-
10 h -1h
metaphase
G1
anaphase
telophase
Cell growth and cell division are divided (mitosis), two daughter cells are devel-
into several phases: synthesizing and oped. Before and after the mitosis, there
doubling of the DNA take place in the are two “resting“ phases (G1- and G2-
S-phase (synthesis). During the M-phase phase).
Source: Pschyrembels Medizinisches Wörterbuch. de Gruyter Verlag, Berlin
6
Mode of Action
7
Mode of Action
Table 1:
Cytostatic mechanisms of action of selected active substances
8
Safety
9
Safety
10
Safety
All new employees handling cytotoxic Through monitoring, the improper han-
materials should receive adequate dling of cytostatic drugs can be detected
education and training, and should be (during in-house investigations in hospi-
regularly retrained. tal pharmacies, traces of cyclophospha-
The employees must be aware of the mide were even found on door handles).
hazards, able to act responsibly, and know In addition, the efficiency of cleaning
how to react in emergencies. The training procedures can be closely monitored.
measures are to be documented, conti-
nuously improved and updated. An Personnel handling cytostatic drugs
important component of any training should be examined regularly (at least
program is practical experience based on once annually) as part of an occupa-
a theoretical foundation. A recommended tional health program.
training outline is provided in the Appen-The main parts of the examination should
dix. In order to be able to look up neces-be tests regarding disturbance of the
sary information, participants of the respiratory organs, therapy-resistant skin
training should be supplied with detailed irritations, as well as liver, renal, and
reference material. haematological malfunctions. If substan-
tial contamination is suspected, biological
For all areas in which cytostatic drugs monitoring by analysis of the urine and
are handled, separate operating pro- blood for cytostatic drugs handled by the
cedures containing the following person or other appropriate assays, may
points are to be provided: be recommended by the examining
● Hazards for humans and the health care professional.
environment
● General handling
● Emergency response
● First aid
● Spill clean-up
● Waste disposal
● Training documentation for each
person
Standard operating procedures for differ-
ent areas are provided in the Appendix.
11
Safety
Generally, every delivery of medicines this case are described in the "Cleaning
should be checked for cytostatic drugs. If Procedures after Accidents“ and "First Aid"
broken packages are detected, they are to sections and in the operating instructions.
be handled within a separate work area The larger the quantities of cytostatic
(e.g., a safety cabinet). Because whole- drugs to be supplied, stored, transported,
salers usually only handle medications and delivered, the greater the likelihood of
that are packed in several layers, there is accidents. Therefore, to avoid glass break-
little health risk for personnel during rou- age, special care is necessary when loading
tine activities. Therefore, protective cloth- and unloading packages (which can be
ing need only to be worn after accidents broken and therefore contaminated) as
or if any container appears broken or well as when storing them on high-rise
leaking. The recommended procedures in shelves.
Reconstitution of Intravenously
Administered Cytostatics Fig. 3:
Biological Safety Cabinet
C
The reconstitution of cytostatic solutions The airflow within the cabinet
should be performed according to good must be laminar and vertical.
The exhausted air is ideally
manufacturing practice (GMP) in safety A ducted outside of the building.
cabinets. Safety cabinets provide person-
nel with protection from aerosols and B
Ambient Air
dust (in particular by air movement and Contaminated Air
filtering – see Fig. 3). Filtered Air
A: Sash
B: Working Surface
C: Exhaust Filter
12
Safety
✓ Within the safety cabinet, the quality of airflow may not be equal in all
regions. Therefore, work at least 10 - 15 cm away from all side edges.
✓ Always leave the safety cabinet turned on (24 hours a day, 7 days a week);
if there is no one working there for longer periods, such as at night and at
weekends, reduce but do not stop the airflow.
13
Safety
For work in a safety cabinet, a liquid- Since vials could be broken in transport or
proof gown (that covers the torso) as well contaminated on the outside when filled
as double-layer sleeve-covering gloves with medicines, gloves and a gown must
are recommended as protective clothing. be worn during unpacking. Wherever
The glove material should be to at least possible, use sealed transport systems.
0.3 mm thick. Glove materials include Any contaminated parts after a
latex, neoprene, polyurethane and nitrile. leakage must not be touched
Powder-free latex and nitrile gloves are directly with the gloves
available in adequate thickness. Because alone, use an additional swab
neither of these materials is completely or similar material. When
impermeable to every cytostatic agent, substances must be dissolved in sealed
the gloves are to be changed at least vials, a positive pressure inside the vial
every 20 minutes or immediately in case may result from the solvent injection,
of visible contamination or damage. increasing the risk of aerosol releases or
When working with very lipophilic splashing when the needle is removed.
cytostatic drugs, such as carmustine, Therefore, reconstitution devices like
gloves are to be changed immediately chemo mini-spikes and liquid-proof
after reconstitution. absorbent mats are recommended.
14
Safety
✓ Use a swab or a cotton pad when injecting into a cytostatic drug solution.
✓ Fill the infusion system with the carrier solution (usually physiological
saline solution).
✓ Always inject into standing infusion bottles. Never inject into hanging
bottles.
✓ When the application is finished, do not remove the infusion system from
the bottle and do not break it off, but dispose of the bottle and infusion
system as a unit.
*All connections should be made with a Luer Lock system to ensure correct and safe connection even under pressure.
15
Nursing
✓ Cover the mattress of the patient bed with a protective plastic layer.
✓ Dispose of patient excretions into the sewage system, if this conforms to
local regulations.
✓ Wear protective gloves and a gown while handling patient excretions.
Special care is needed when cleaning the containers.
✓ Contaminated linen should be put into the laundry bag immediately.
Wear protective gloves and a gown to do so. The laundry bag is to be
clearly labeled to inform the laundry personnel of potential hazards.
Extravasations
If extravasations occur, the following The subsequent therapy of extravasations
rules are to be followed: is controversial and depends on the par-
1. Stop the infusion – Do not remove ticular cytostatic drug (see references in
the canula! the Appendix and contact the manu-
2. Inform a physician. facturer).
3. Aspirate the extravasated drug.
16
Home Care
17
Disposal
18
Disposal
Before disposal in special containers, the Furthermore, it must be noted which sub-
strongly contaminated cytostatic drug stances and metabolites result from this
wastes are to be sealed into plastic bags. treatment and the degree of their risk-
Special devices are not necessary, and potential. In addition, it must be proven
a domestic heat sealer is sufficient. that a mutagenic potential no longer
Cytostatics can also be inactivated by exists. The remaining solutions cannot
chemical reactions. Most inactivation simply be flushed away in the sewage
methods are very complicated and should system. In most countries, they must be
be carried out with well-founded disposed of in accordance with their
chemical knowledge and duly observing potential hazard. For these reasons,
industrial safety standards. In a hospital, chemical inactivation of the cytostatic
this is only possible in laboratories or in drugs is not advised.
the pharmacy.
19
Cleaning
20
Cleaning
21
First Aid / Environment
22
Checkliste
Hersteller
Appendix
Contents
23
Checklist
Checkliste
Hersteller
24
Checkliste
Hersteller
Checklist
14 - B 13 - E 12 - C
11 - A 10 - A 9-E 8 - B, C
7 - B, C 6-A 5-B 4-H
3-A 2-G 1-F Solutions:
25
Schulung
Training
● Behaviour in emergencies
• First aid measures
• Contact persons (Health
Surveillance Services, Poison
Control Center)
26
Training
Hersteller
Schulung
Subject of course:
Date: Location:
Subjects:
Topics discussed:
Trainer:
Participants:
Name Signature
27
Number:
28
General handling
Irritant (Xi)
● Reconstitution has to take place in a safety cabinet with laminar and vertical airflow.
● Wear liquid-proof protective gloves and a liquid-proof gown.
● Change gloves frequently, e.g., at least every 20 minutes, or immediately in the case of visible
contamination.
Toxic (T)
● Use a liquid-proof absorbent mat and reconstitution devices when reconstituting in sealed vials.
Very toxic (T )
+
● Leave ventilation slots uncovered.
● After finishing work, clean the work surface with water and afterwards with 70 percent
alcohol.
Dangerous for ● Do not turn off the safety cabinet, even after use.
● Service the safety cabinet periodically, in accordance with the manufacturer’s
the environment (N)
recommendations.
● Label the containers for in-house transport.
Behaviour in emergencies (Emergency Tel.: )
● After spillage of cytostatic drugs, the contaminated area is to be isolated and cleaned immediately.
● Wear liquid-proof gloves and a gown, a respirator mask, and safety goggles during cleaning.
● Use a spill kit.
● Soak up spilled substances with sufficient quantities of absorbent material; avoid dust-raising and aerosol production.
● Clean biological safety cabinet first with 70 percent alcohol and then with a detergent solution.
● Dispose of contaminated materials as special waste.
For additional information, ask your doctor or pharmacist, or your safety or environ-
mental expert.
29
Number:
30
For additional information, ask your doctor or pharmacist, or your safety or environ-
33
mental expert.
Safety
34
Safety
Cytotoxic Excretion rate Duration after therapy for which protective cloth-
ing is recommended when handling excreta*
Sources: Harris and Dott (1985); Cass and Musgrave (1992); Graijny et al. (1993); Micromedex™ Drug Data Base (1997); Dimtscheva
et al. (1998)
35
First Aid
* For further information see material safety data sheet supplied by the manufacturer
36
Accident Report Form
1. Personal data
first name: last name:
activity:
❏ reconstitution ❏ application ❏ nursing
❏ other:
2. Accident
means of contamination:
❏ skin contact ❏ eye contact ❏ inhalation
❏ ingestion ❏ other:
doctor contacted:
37
Documentation
Example for
Documentation of Cytostatic Drug Handling
Employee:
Etoposid 230
Carboplat 1530
Etoposid 420
5-Fluorouracil 3000 bottle was contaminated
Ifosfamide 5400
38
References
References
SESSINK PJM, KROESE ED, VAN KRANEN HJ and BOS
RP (1995) Cancer risk assessment for health care workers
➟ A. General
ALLWOOD M, WRIGHT P and STANLEY A (Hrsg.) (1997)
occupationally exposed to cyclophosphamide. Int Arch
Occup Environ Health 67, 317-323
The Cytotoxics Handbook (3. Auflage). Radcliffe Medical VAITEKUNAS H and MÜLLER-BOHN T (1996) Zytosta-
Press Oxford tikazubereitung in der Apotheke. Der Weg zu sicherem
BARTH J (1996) Neuere Zytostatika. Krankenhausphar- Arbeiten und einwandfreien Produkten. Deutsche Apo-
mazie 17, 570-581 theker-Zeitung 1 36, 1204-1212
SAUER, H (1995) Zytostatika, Hormone. Zytokine. Thieme WAKSVIK H, KLEPP O and BROGGER A (1981) Chro-
Verlag Stuttgart mosome analyses of nurses handling cytostatic agents.
BRISTOL-MYERS SQUIBB (1993) Safe handling of Cancer Treat Rep 65, 607-610
hazardous drugs WILKEN A (1997) Beobachtungen zur Außenkontamina-
TRGS 525: Umgang mit Gefahrstoffen in Einrichtungen tion der Primärverpackungen von Zytostatika. Kranken-
der humanmedizinischen Versorgung hauspharmazie 18, 37-39
DORR RT (1990) Antidotes to vesicant chemotherapy JF and ZIMMERMAN PF (1984) Disposal of antineopla-
extravasations. Blood Reviews 4, 41-60 stic wastes at the National Institutes of Health. Am J
FITZEL E (1992) Behandlung von Zytostatikaparavasa- Hosp Pharm 41, 87-93
ten. Krankenhauspharmazie 13, 344-346
HARWOOD K and HERRMANN R (1994) Extravasation ➟ F. Home care
GRAJNY AE, CRISTIE D, TICHY AM and TALASHEK ML
in intravenous chemotherapy. Deutsche Medizinische
(1993) Chemotherapy: how safe for the caregiver? Home
Wochenschrift 119, 359-360
Healthcare Nurse 11, 51-58
LARSON DL (1982) Treatment of tissue extravasation by
LOWENTHAL RM, PIASZCZYK A, ARTHUR GE and
antitumor agents. Cancer 49, 1796-1799
O’MALLEY S (1996) Home chemotherapy for cancer
LLOP JC, MATEU J and LLORENTE A (1993) The extra-
patients: cost analysis and safety. Medical Journal of
vasation of cytostatic drugs: its diagnosis, evolution and
Australia 165, 184-187
treatment. Medicina Clinica 101, 105-109
WITTEVEEN PO, VAN BOXTEL AJ, NIEUWLAND M,
MATEU J and LLOP C (1994) Delayed treatment of vin-
NEIJT JP and BLIJHAM GH (1995) Feasibility of trans-
desine extravasation. Annals of Pharmacotherapy. 28,
ferring medical-technological aid to the home situation
967-968
for patients with cancer or a serious infection. Neder-
RUDOLPH R and LARSON DL (1987) Etiology and
lands Tijdschrift voor Geneeskunde 139, 788-791
treatment of chemotherapeutic agent extravasation
injuries: A review. J Clin Oncol 5, 1116-1126
SCHÖNBORN I (1990) Umgang mit Zytostatika aus der
➟ G. Environmental impact of cytostatics
AL-AHMAD A, KÜMMERER K und SCHÖN G (1997)
Sicht des Arztes. Krankenhauspharmazie 11, 487-488 Biodegradation and toxicity of the antineoplastics Mitox-
SHENAQ SM, ABBASE EH and FRIEDMAN JD (1996) antron hydrochloride and Treosulfane in the Closed Bottle
Soft-tissue reconstruction following extravasation of Test (OECD 301 D) Bull Environ Contam Toxicol 58, 704-711
chemotherapeutic agents. Surgical Oncology Clinics of KÜMMERER K und AL-AHMAD A (1997) Biodegrada-
North America. 5, 825-845 bility of the anti-tumour agents 5-Fluorouracil, Cytara-
VAN SLOTEN HK (1987) Treatment of anthracycline bine and Gemcitabine: Impact of the chemical structure
extravasation – recommendations for practice. J Clin and synergistic toxicity with hospital effluent. Acta
Oncol 5, 705 hydrochim hydrobiol 25, 166-172
KÜMMERER K und HELMERS E (1997) Hospital efflu-
➟ E. Disposal of cytostatic waste
AMERICAN SOCIETY OF HOSPITAL PHARMACISTS
ents as a source for platinum in the environment. Sci Tot
Environ 193, 179-184
CLINICAL AFFAIRS DEPARTMENT (1990) ASHP techni- KÜMMERER K, AL-AHMAD A und STEGER-HART-
cal bulletin on handling cytotoxic and hazardous drugs. MANN T (1996) Verhalten des Zytostatikums Epirubicin-
Am J Hosp Pharm 47, 1033-1049 Hydrochlorid in der aquatischen Umwelt - erste Ergeb-
HARRIS J und DODDS (1985) Handling waste from nisse. Umweltmed Forsch Prax 1, 133-137
patients receiving cytotoxic drugs. The Pharmaceutical AL-AHMAD A und KÜMMERER K Biodegradation
Journal 235, 289-291 of the antineoplastics Vindesine, Vincristine and Vin-
LÄNDERARBEITSGEMEINSCHAFT ABFALL ARBEITS- blastine and toxicity against bacteria in the aquatic
GRUPPE ENTSORGUNG VON ABFÄLLEN AUS environment. Cancer Det. Prev., accepted for publication
ÖFFENTLICHEN UND PRIVATEN EINRICHTUNGEN KÜMMERER K, AL-AHMAD A, BERTRAM B und
DES GESUNDHEITSDIENSTES (1992) Merkblatt über die WIEßLER M (2000) Biodegradability of antineoplastic
Vermeidung und die Entsorgung von Abfällen aus compounds in screening tests: Improvement by glucosi-
öffentlichen und privaten Einrichtungen des Gesund- dation and influence of stereochemistry. Chemosphere,
heitsdienstes. Bundesgesundhbl 1992; 30-38 40, 767-773
OCCUPATIONAL SAFETY AND HEALTH ADMINISTRA- KÜMMERER K, STEGER-HARTMANN T und MEYER M
TION (1995) OSHA Instruction TED 1.15 Section V: (1997) Biodegradability of the anti-tumour agent ifosfami-
Chapter 3: Controlling occupational exposure to hazar- de and its occurrence in sewage. Wat. Res., 31, 2705-2710
dous drugs. V:3-1 - V:3-31 KÜMMERER K, AL-AHMAD A (1998) Estimation of the
ÖSTERREICHISCHES NORMUNGSINSTITUT (1992) cancer risk for humans related to cyclophosphamide and
ÖNORM S 2104 Abfälle aus dem medizinischen ifosfamide excretions emitted into surface water via
Bereich. Wien, Österreichisches Normungsinstitut hospital effluents. Cancer Detection and Prevention 22,
SCHERRER M, DASCHNER F, STREHL E and VAN Supplement 1/1998, 136. Cancer Det and Prev, submitted.
GEMMERN R (1997) Zytostatika: Umgang und Entsor- STEGER-HARTMANN T, KÜMMERER K und HART-
gung. Krankenhauspharmazie 18, 176-178 MANN A (1997) Biological degradation of cyclophos-
VACCARI PL, TONAT K, DECHRISTOFORO R, GALLELLI phamide and its occurence in sewage water. Exotoxicol
Env Saf 36, 174-179
40
List of Manufacturers
Gloves
Regent Hospital Products
Broxbourne EN106LN, U.K.
Telephone: +44/1992451111
Paul Hartmann AG
P.O. Box 1420
D-89504 Heidenheim, Germany
Telephone: +49/7321-36-0
Fax: +49/7321-36-3636
List of Manufacturers Allegiance Healthcare Corporation
1430 Waukegan Rd.
McGaw Park, Illinois 60085, U.S.A.
Telephone: +1/847-689-8410
The following list does not claim to be complete. Internet: http://www.allegiance.net
Please tell us if you have any suggestions for
improvement so that we can include them in SCA Hygiene Products
the next updated version. P.O. Box 1429
D-85732 Ismaning
Germany
Safety cabinets Telephone: +49/8035/800
Fax: +49/8035/80412
Heraeus Instruments GmbH Internet: http://www.sca.se
P.O. Box 1563
D-63405 Hanau Berner International GmbH
Germany Mühlenkamp 6
Telephone: +49/6181/35-300 D-25337 Elmshorn, Germany
Fax: +49/6181/355973 Telephone: +49/4121/4356-0
Internet: http://www.heraeus.de Fax: +49/4121/4356-20
Labconco Corporation
8811 Prospect Avenue Gowns
Kansas City, MO 64132-2696
U.S.A. Kimberly Clark
Telephone: +1/800-821-5525 World Headquarters
Fax: +1/816-363-0130 P.O. Box 619100
Internet: http://www.labconco.com Dallas, Texas 75261-9100 U.S.A.
E-Mail: labconco@labconco.com Telephone: +1/800/742-1996
(Customer Service Department)
NUAIRE, Inc. Internet: http://www.kimberly-clark.com
2100 Fernbrook Lane
Plymouth, MN 55447-4722 3M Medical-Surgical Division, 3M Health Care,
U.S.A. 3M Center, Building 275-4E-01,
Telephone: +1/612-553-1270 St. Paul, MN 55144-1000 U.S.A.
Internet: http://www.nuaire.com Telephone: +1/800-228-3957
E-Mail: nuaire@nuaire.com Fax: +1/612-733-9596.
E-mail: healthcare@mmm.com
HEMCO Internet: http://www.mmm.com
111 N. Powell Rd.
U.S.A. Allegiance Healthcare Corporation
Independence, MO 64056, U.S.A 1430 Waukegan Rd.
Telephone: +1/816-796-2900 McGaw Park, IL 60085 U.S.A.
Fax: +1/816-796-3333 Telephone: +1/847-689-8410
Internet: http://www.allegiance.net
Berner International GmbH
Mühlenkamp 6 Sage Products Inc.
D-25337 Elmshorn 815 Tek Drive
Germany Crystal Lake, IL 60014-9693 U.S.A.
Telephone: +49/4121/4356-0 Telephone: +1/800-323-2220
Fax: +49/4121/4356-20 Fax: +1/815-455-5599
E-Mail: customerservice@sageproducts.com
Internet: http://www.sageproducts.com
41
List of Manufacturers
42
ISBN 3-00-004032-3